Fecal Incontinence Therapeutics Market is Segmented By Diagnosis (Digital rectal exam, Balloon expulsion test, Anal manometry, Anorectal ultrasonography, Proctography, Colonoscopy, Magnetic resonance imaging (MRI), Others), By Treatment (Medications, Exercise and Therapies, Surgery, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), By End-User (Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Center, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
Fecal Incontinence Therapeutics Market is estimated to reach at a high CAGR 3.5% during the forecast period (2024-2031).
Fecal Incontinence (FI) is when people lose control of their bowel motions, resulting in involuntary feces leakage. Constipation, diarrhea, and nerve degeneration caused by aging cause bowel incontinence, also known as bowel incontinence. Depending on the cause of fecal incontinence, treatment can include one or more of these approaches: dietary changes, bowel training (biofeedback), medications or surgery.
Market Dynamics
Innovations and prospects for fecal incontinence treatment are expected to drive market growth.
Dielectric electroactive polymer actuators are particularly attractive because of their adaptability, response time, reaction forces, and energy consumption. Such technology will allow for rapid pressure adaptation, similar to the natural feedback system, avoiding tissue atrophy and erosion while preserving continence during daily activities. Moreover, new digital Phone APPs such as Constipation Stool diary, My GI App, and Fecal Incontinence stool diary can be useful tools for patients and clinicians for accurate recording and monitoring of bowel symptoms. Additionally, the diagnosis of these issues is essentially clinical, with radiography and manometric techniques supporting it. High-resolution anorectal manometry, high-quality 3-D anorectal manometry with TachArray, and 256 pressure sensor probe are all fantastic new diagnostic techniques today. The translumbosacral anorectal magnetic test for neurophysiology and balloon expulsion and colon transit tests are additional tools. Thus, the market is expected to drive in the forecast period from the above statements.
Restraint:
Side effects associated with the drugs is expected to hamper the market growth.
COVID-19 Impact Analysis
The COVID-19 pandemic has moderately impacted healthcare systems and the market. Lockdown periods, in which individuals were not allowed to leave their homes for several days, were one of these limitations. These policies had a significant impact on people's everyday lives, lifestyles, eating habits, and mental health. In several studies, a lack of physical exercise and a sedentary lifestyle have been related to an increased risk of developing Lower Urinary Tract Symptoms (LUTS) and bowel dysfunction. Likewise, some research has found a link between a sedentary lifestyle and depression, which, together with anxiety, is a known risk factor for developing LUTS or bowel dysfunction. Moreover, during lockdown periods necessitating additional monitoring, healthcare personnel should emphasize the necessity of maintaining a routine, and preventive actions such as home exercise instructions and phone follow-up are taken.
Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.
Market Segment Analysis
Medications segment is expected to hold the largest market share in fecal incontinence therapeutics market
The medications segment is expected to dominate in 2021. The segment's growth is beneficial because anti-diarrheal medicines and fiber supplements are commonly recommended medications. These drugs slow down the flow of the stool through the colon and make it firmer. For instance, Bulk laxatives, such as Citrucel and Metamucil, are sometimes recommended by doctors to help patients create more firm stools that are simpler to regulate. Anti-diarrheal drugs like loperamide or diphenoxylate are prescribed to help control the condition and slow down the bowels. Therefore, it has increased the demand for drugs. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Market Summary
| Metrics | Details |
| Market CAGR | 3.5% |
| Segments Covered | By Diagnosis, By Treatment, By Distribution Channel, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more details on this report – Request for Sample
Market Geographical Share
North America region holds the largest market share in the global fecal incontinence therapeutics market
In 2021, North America accounted for the highest revenue share. The increasing prevalence of fecal incontinence, rising geriatric population, well-established infrastructure, advancement in diagnosis, higher adoption of drugs and increasing clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, Fecal incontinence affects almost 18 million persons in the United States or around one in every twelve. Bowel control issues can affect people of any age, but fecal incontinence is more common among the elderly. Women are slightly more likely than men to experience fecal incontinence.
Moreover, Cook MyoSite is looking into Autologous Muscle-Derived Cells to see if they might help patients with sphincter function. The business is conducting a Phase I/II prospective nonrandomized trial and is expected to be completed by October 2021. Additionally, Meters Biopharma is also conducting trials for RDD-0315 and has previously reported good Phase II findings for RDD-0315 in treating fecal incontinence in individuals with spinal cord injuries. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.
Market Competitive Landscape
Major key players in the fecal incontinence therapeutics market are Johnson & Johnson Consumer Inc., Napo Pharmaceuticals, Inc., Procter & Gamble, Arcadia Consumer Healthcare, Avrio Health L.P, Chattem, Inc., Prestige Consumer Healthcare Inc., GlaxoSmithKline plc.
Procter & Gamble:
Overview:
The Procter & Gamble Company (P&G) is an American multinational consumer goods corporation headquartered in Cincinnati, Ohio, founded in 1837. It specializes in a wide range of personal health/consumer health and personal care and hygiene products; these products are organized into several segments, including beauty, grooming, health care; fabric & home care; and baby, feminine, & family care. P&G is streamlining the company, dropping and selling off around 100 brands from its product portfolio to focus on the remaining 65 brands, which produce 95% of its profits.
Product Portfolio:
Pepto-Bismol LiquiCaps: This medicine is used for heartburn and acid reflux, indigestion, diarrhoea and feeling sick (nausea). It works by protecting your stomach and the lower part of your food pipe from stomach acid. It is also a mild antacid, which helps reduce excess stomach acid and eases any discomfort.
